Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00680628 · ClinicalTrials.gov registry record · Phase 3
Clot Dissolving Treatment for Blood Clots in the Lungs
A Phase 3 study, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- Phase 3
- Development phase
- 83
- Enrollment target
NCT00680628: Clinical Trial Phase 3 study, sponsored by Wake Forest University Health Sciences.
NCT00680628 is a Phase 3 study that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 83 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00680628, a Phase 3 study, was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 83 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if tenecteplase plus enoxaparin is safe and effective in the treatment of patients with severe submassive pulmonary embolism.
Interventions
- DRUG Tenecteplase + Enoxaparin
- DRUG 0.9% Saline + Enoxaparin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2008-05 |
| Est. Completion | 2012-10 |
| Phase | Phase 3 |
Why NCT00680628 stopped before completion
NCT00680628 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 83 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 2 interventions - of which Tenecteplase + Enoxaparin is the first listed.
NCT00680628 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00680628 about?
NCT00680628 is a clinical study titled "Clot Dissolving Treatment for Blood Clots in the Lungs". The purpose of this study is to determine if tenecteplase plus enoxaparin is safe and effective in the treatment of patients with severe submassive pulmonary embolism.
What is the current status of trial NCT00680628?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 83 participants. The study started on 2008-05. Estimated completion is 2012-10.
What interventions are being tested in trial NCT00680628?
The interventions under investigation include: Tenecteplase + Enoxaparin (DRUG), 0.9% Saline + Enoxaparin (DRUG).
Who is sponsoring clinical trial NCT00680628?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00680628's enrollment target sits among peer trials
83 1751st of 2000 higher than 249 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02974647 · 83 participants · Phase 2
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
- NCT03919292 · 83 participants · Phase 1
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
- NCT04626674 · 83 participants · Phase 1
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
- NCT05277168 · 83 participants · Phase 1
A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia